Drug Database
PA

paracetamol + domperidone (Domvas)

✓ Approved

A. N. Pharmacia Laboratories · DRD2 · 小分子

什么是 paracetamol + domperidone?

paracetamol + domperidone 是一种小分子,由A. N. Pharmacia Laboratories研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Domvas
公司A. N. Pharmacia Laboratories
药物类别小分子
分子靶点DRD2, PTGS1, PTGS2
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

paracetamol + domperidone 作用于 3 个分子靶点:

DRD2dopamine receptor D2 (D2R, D2DR)
PTGS1prostaglandin-endoperoxide synthase 1 (PGHS1, COX1)
PTGS2prostaglandin-endoperoxide synthase 2 (PGG/HS, PGHS-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

paracetamol + domperidone 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersMigraine✓ Approved

相关研究文献

PubMedAsian journal of anesthesiology2026-11-19

Comparative Study Between Analgesic Effects of Quadratus Lumborum Block (QLB) and Intravenous Analgesia in Patients Undergoing Nephrectomy.

Bodavula Venkata Naga Siva Sai Sandeep VNSSS, Chinthalapudi Mounika M, K Ragha Deepti RD

Nephrectomy is associated with significant postoperative pain due to surgical trauma and visceral manipulation. Intravenous opioids are commonly used for analgesia but may cause systemic adverse effects. This study compared postoperative analgesic outcomes between quadratus lumborum block (QLB) and conventional intravenous analgesia (IVA) in patients undergoing nephrectomy. This hospital-based observational study included 60 patients, with 30 patients in each group. Group I received QLB with 0.25% bupivacaine, while Group II received conventional IVA. Postoperative pain was assessed using the visual analogue scale (VAS) every two hours for 24 hours. Sedation was evaluated using the Modified Ramsay Sedation Score. Hemodynamic parameters, intraoperative fentanyl use, and postoperative tramadol and paracetamol consumption were recorded. Data were analyzed using SPSS v26.0. Intergroup comparisons were performed using independent t-tests. VAS scores were significantly lower in the QLB group during the first 8 postoperative hours ( P < 0.001). Intraoperative fentanyl (100.00 µg vs. 161.67 µg), postoperative tramadol (61.67 mg vs. 148.33 mg), and paracetamol consumption (2.23 g vs. 3.27 g) were lower in the QLB group. Time to first rescue analgesia was longer in the QLB group (4.52 hours vs. 0.43 hours; P = 0.001). Sedation scores were lower during the first 4 hours. Intraoperative hemodynamic parameters also differed between groups, although baseline mean arterial pressure was significantly lower in the QLB group. QLB was associated with lower early postoperative pain scores, reduced analgesic requirements, and longer time to first rescue analgesia compared with IVA. The observational design limits causal interpretation of these findings.

PMID 43053653
阅读全文 →
PubMedSage open pediatrics2026-11-18

Management Practices and Clinical Profiles of Pediatric Pneumonia in a Tertiary Referral Setting in Ethiopia: A Retrospective Cross-Sectional Study.

Wake Sagni Lema SL, Woldu Minyahil Alebachew MA

Pneumonia remains a major cause of hospitalization among children in Ethiopia. To describe clinical characteristics, treatment practices, and outcomes. A retrospective cross-sectional chart review was conducted between November 2023 and March 2024 (n=207). Descriptive and exploratory regression analyses were used. Severe pneumonia accounted for 93.7% of cases, with community-acquired pneumonia predominating. Ceftriaxone was the most frequently used antibiotic (32.2%), while paracetamol was the most commonly administered supportive medication (84.8%). More than half of patients (55.1%) were hospitalized for 1-2 weeks. A history of pneumonia, comorbidity, recurrent respiratory illness, and acute malnutrition were associated with prolonged hospitalization. Blood culture testing was performed in only seven patients. Overall, 92.8% of patients recovered or improved, while 7.2% experienced poor outcomes. Regression findings were interpreted as exploratory given the small number of poor-outcome events. Severe pneumonia was common, with substantial use of broad-spectrum antibiotics and limited microbiological investigation.

PMID 43047839
阅读全文 →
PubMedAnaesthesia, critical care & pain medicine2026-11-18

Scoping review on dosing of anaesthetic and perioperative drugs in patients with obesity: which body weight for which molecule.

Gouel-Chéron Aurélie A, Aubrun Frédéric F, Aubrun Frédéric F, Garnier Marc M et al.

The prevalence of obesity is rising. Patients with obesity are increasingly exposed to anaesthesia, critical care, and perioperative pharmacotherapy. Obesity alters drug pharmacokinetics in a non-linear, drug-specific manner, so that simply scaling doses to total body weight (TBW) exposes patients to overdose or underdose. A recurring clinical question is therefore: which body weight descriptor should be used for which molecule? This review was conducted in accordance with the PRISMA extension for Scoping Reviews. We synthesized pharmacokinetic evidence, recent meta-analyses, and French and European guidelines on dose adjustment in adults with obesity for five drug classes of anaesthesia and critical care: hypnotics, opioids, neuromuscular blocking agents (NMBA), perioperative antibiotics, and non-opioid analgesics. We summarised the recommended dosing weight for each molecule in a table and a figure. No single weight descriptor applies. Lipophilic induction agents (propofol), most opioids (alfentanil, fentanyl, sufentanil), and non-depolarising NMBA are best dosed on lean or ideal body weight, whereas succinylcholine, neuromuscular reversal, and aminoglycosides use total or adjusted body weight. Maintenance of hypnosis and pain management in the post-anaesthesia care unit are titrated to monitored effect. Cephalosporin-based antibiotic prophylaxis relies on fixed doses (e.g., cefazolin 2 g) up to high body mass index values due to their hydrophilic properties. Paracetamol and non-steroidal anti-inflammatory drugs are given at standard doses and never scaled to TBW. Findings are consolidated in a single bedside reference table. Dosing in obesity must be molecule-specific, guided by the relevant weight descriptor and by intraoperative monitoring rather than by TBW alone.

PMID 43051533
阅读全文 →
PubMedThe Cochrane database of systematic reviews2026-11-18

Curcuma longa (turmeric) or its active ingredients for osteoarthritis.

Shirinsky Ivan I, Shirinsky Valery V, Filatova Katerina K, Yu Ze Yu ZY et al.

Osteoarthritis is a major cause of disability worldwide. Current treatments have limited efficacy. Curcuma longa (turmeric) contains curcuminoids with anti-inflammatory properties that may modulate osteoarthritis pathophysiology. However, the clinical benefits and safety of Curcuma longa in osteoarthritis remain uncertain. To assess the benefits and harms of Curcuma longa extracts or сurcuminoids for osteoarthritis. We used CENTRAL, MEDLINE, five other databases, and two trials registers, together with reference checking, to identify the studies included in the review. The latest search date was 7 November 2025. We applied no restrictions on language, publication date, or publication status. We included randomised controlled trials (RCTs) comparing Curcuma longa extracts or curcuminoids to placebo, in people with osteoarthritis in any joint. Other comparators included no treatment, non-steroidal anti-inflammatory drugs (NSAIDs), non-NSAID analgesics, or other active comparators. We focused on oral formulations of Curcuma longa, with or without bioavailability enhancers, and excluded combination products containing other active herbal compounds. Critical outcomes included pain, function, quality of life, participant-reported global assessment of success, adverse events, withdrawals due to adverse events, and serious adverse events. The primary time point was up to three months. We used Cochrane's RoB 2 tool to assess bias in the RCTs. We used a random-effects model for meta-analysis. We assessed the trustworthiness of all trials eligible for inclusion using the Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool. We included nine RCTs involving 1245 participants with knee osteoarthritis. The mean age of participants ranged from 52 years to 62 years; 67% of participants were female. All trials were short (up to 90 days) and investigated different Curcuma longa formulations. One trial evaluated a bioavailability-enhanced Curcuma longa formulation, while others did not report the use of bio-enhancers. Two trials used Curcuma longa extract with essential oils. Four trials used standardised or rhizome extracts of Curcuma longa, with curcuminoid content varying from 23% to 88%. Four trials compared Curcuma longa with placebo (379 participants), four with NSAIDs (673 participants), and one with paracetamol (193 participants). Here, we limit reporting to the primary comparison, Curcuma longa versus placebo. We judged three (75%) placebo-controlled trials to be at low risk of bias for pain, function, and quality of life outcomes. Two trials (50%) were at low risk of bias for safety outcomes. Low-certainty evidence downgraded for indirectness and publication bias showed that, compared with placebo, Curcuma longa may result in little to no difference in pain, function, or quality of life, and may improve participant-reported global assessment of success. We are very uncertain about the effect of Curcuma longa on adverse events, withdrawals due to adverse events, and serious adverse events due to very low-certainty evidence, downgraded for publication bias, imprecision, and indirectness. By three months, the mean change in pain (0 to 10 scale, 0 = no pain) was -1.57 points with placebo and 0.72 points lower (95% confidence interval (CI) 1.39 points lower to 0.06 points lower) with Curcuma longa (I² = 0%; 4 studies, 349 participants). The effect did not reach clinical significance of 1.5 points. By three months, the mean change in function (0 to 100, 0 = best function) was -5.42 points with placebo and 3.5 points lower with Curcuma longa (95% CI 7.29 points lower to 0.29 points higher; I² = 0%; 4 studies, 348 participants). By three months, the mean change in quality of life (0 to 100 scale, 100 = best quality of life) was 9.83 points with placebo and 2.19 points higher (95% CI 1.56 points lower to 5.94 points higher) with Curcuma longa (I² = 0%; 3 studies, 291 participants). By three months, 107 of 1000 participants receiving placebo reported treatment success, compared with 191 of 1000 receiving Curcuma longa (risk ratio (RR) 1.78, 95% CI 1.19 to 2.67; 2 studies, 170 participants). At the end of follow-up, 224 of 1000 participants in the placebo group reported adverse events compared with 226 of 1000 in the Curcuma longa group (RR 1.01, 95% CI 0.68 to 1.51; I² = 0%; 4 studies, 379 participants). At the end of follow-up, 46 of 1000 participants in the placebo group withdrew due to adverse events compared with 66 of 1000 in the Curcuma longa group (RR 1.45, 95% CI 0.61 to 3.43; I² = 0%; 3 studies, 321 participants). Three trials reported no serious adverse events, while one trial reported two serious adverse events in the placebo group that were unrelated to the study. Compared with placebo, Curcuma longa may result in little to no improvement in pain, function, or quality of life, and may improve participant-reported global assessment of success in people with knee osteoarthritis. We are very uncertain about the effect of Curcuma longa on adverse events, withdrawals due to adverse events, and serious adverse events. Future studies should last longer than three months; the maximum duration of the included studies was three months. The current evidence is limited to knee osteoarthritis, and future studies should include people with hand and hip osteoarthritis. No external funding was received for this work. Protocol (2021): 10.1002/14651858.CD014683.

PMID 43051256
阅读全文 →
PubMedTherapie2026-11-17

[Effectiveness of paracetamol in the treatment of hip and knee osteoarthritis pain in adults: Literature review and meta-analysis REB].

Blanpain Amélie A, Boussageon Rémy R

To evaluate the efficacy of paracetamol versus placebo on hip and knee osteoarthritis pain in adults. Systematic review and meta-analysis of double-blind randomized controlled trials (RCTs) with interpretation of results according to the REB method, incorporating assessment of risk of bias and distinction between confirmatory and exploratory endpoints. The eligibility criteria were RCTs evaluating the analgesic efficacy of paracetamol versus placebo in adults with hip and knee osteoarthritis. Searches were conducted on Medline, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov up to February 28, 2025. Risk of bias was assessed using the Risk of Bias 2 tool. The primary outcome measure was pain intensity relief. The secondary outcome measure was improvement in physical function. Twelve RCTs were included, evaluating 4556 patients followed up for up to 6 months. Five trials assessing pain and four trials assessing physical function were at low risk of bias. The REB method concluded that there was no evidence of the analgesic efficacy of paracetamol and a signal to be confirmed on mid-term physical function: SMD=-0.08 95% CI [-0.19; 0.04]; P=0.19; I2=12%. Unlike previous meta-analyses, the REB method did not find clear evidence of paracetamol's effectiveness in treating knee and hip osteoarthritis pain and only identified a signal requiring confirmation for mid-term physical function. The GRADE method showed statistically significant effects, but these were insufficient in magnitude to be clinically relevant. These results raise questions about the place of paracetamol in the management of osteoarthritis.

PMID 43045597
阅读全文 →
PubMedBMJ paediatrics open2026-11-17

Prenatal paracetamol (acetaminophen) exposure and autism spectrum disorder: a systematic review and Bayesian meta-analysis.

Alotaibi Haifa F HF, Alfraidi Alanoud A, Al Marzoki Kholud K, Taib Hanan H et al.

PMID 43045642
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多paracetamol + domperidone